165 related articles for article (PubMed ID: 10971048)
1. Galantamine: additional benefits to patients with Alzheimer's disease.
Lilienfeld S; Parys W
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():19-27. PubMed ID: 10971048
[TBL] [Abstract][Full Text] [Related]
2. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
3. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
4. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
6. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
7. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
Aronson S; Van Baelen B; Kavanagh S; Schwalen S
Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
[TBL] [Abstract][Full Text] [Related]
8. Galantamine for Alzheimer's disease and mild cognitive impairment.
Loy C; Schneider L
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
[TBL] [Abstract][Full Text] [Related]
9. Galantamine for Alzheimer's disease.
Loy C; Schneider L
Cochrane Database Syst Rev; 2004 Oct; (4):CD001747. PubMed ID: 15495017
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
Bullock R; Erkinjuntti T; Lilienfeld S;
Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
[TBL] [Abstract][Full Text] [Related]
11. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
12. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
13. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
[TBL] [Abstract][Full Text] [Related]
14. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
15. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
Tariot PN
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of galantamine treatment in patients with Alzheimer disease.
Lyketsos CG; Reichman WE; Kershaw P; Zhu Y
Am J Geriatr Psychiatry; 2004; 12(5):473-82. PubMed ID: 15353385
[TBL] [Abstract][Full Text] [Related]
17. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
18. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
19. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.
Wilkinson DG; Hock C; Farlow M; van Baelen B; Schwalen S
Int J Clin Pract; 2002 Sep; 56(7):509-14. PubMed ID: 12296613
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
